The biotechnology company Flex Pharma, Inc. (NASDAQ: FLKS) is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. Flex Pharma’s products will be designed to address muscle cramps and spasms by halting the repetitive firing of the motor neurons. Preliminary testing of those products in humans has shown that they can relieve electrically-induced muscle cramps in minutes, and that the effect lasts for hours. For more information, visit the company’s website at www.flex-pharma.com.